The BRAFV600E mutation suggests that ERK, a downstream effector of BRAF, may play a major role in the carcinogenesis of PTC [33], and is associated with extrathyroid invasion, lymph node metastases, advanced tumor stage, and frequent recurrence [34]. The gene discussed is BRAF; the disease is neoplasm.